Disease · MONDO_0004971

adenoid cystic carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. adenoid cystic carcinoma. Diseases, record MONDO_0004971. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004971

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: adenoid cystic carcinoma; Open Targets
Open Targets ID: MONDO_0004971; Open Targets
Other names: adenocystic carcinoma, adenoid cystic cancer, cylindroid adenocarcinoma; Open Targets
Disease Ontology: DOID:0080202; Disease Ontology
MeSH: D003528; MeSH
NCI Thesaurus: C2970; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 43 of its 61 drugs, from ClinicalTrials.gov; Open Targets

Drugs61

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AXITINIB	CHEMBL1289926	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
LENVATINIB	CHEMBL1289601	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
BECOTATUG VEDOTIN	CHEMBL6068210	Antibody drug conjugate	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DOVITINIB	CHEMBL522892	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
EPIRUBICIN	CHEMBL417	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 61

See all 61 drugs

Targets122

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	9	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	8	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	8	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
ABL1	Bcr/Abl fusion protein	4	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5156	Drugs and targets
BCR	Bcr/Abl fusion protein	3	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
EGFR	Epidermal growth factor receptor	3	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets

1 to 10 of 122

See all 122 targets

Trials55

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03691207	A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations	Phase 2	87	2024-01-31	Adenoid Cystic Carcinoma	OSUGACESTAT	Its record names the disease	ClinicalTrials.gov
NCT03172624	Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer	Phase 2	64	2025-12-18	Salivary Gland Cancer	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00859937	Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors	Phase 2	55	2015-04-03	Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7	DASATINIB ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT01218555	Study of Everolimus (RAD001) in Combination With Lenalidomide	Phase 1	44	2022-01-27	Solid Organ Malignancies, Adenoidcystic Carcinoma, Neuroendocrine Tumors	EVEROLIMUS, LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00095563	Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers	Phase 2	40	2017-04-18	High-grade Salivary Gland Carcinoma, High-grade Salivary Gland Mucoepidermoid Carcinoma, Low-grade Salivary Gland Carcinoma, Low-grade Salivary Gland Mucoepidermoid Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Acinic Cell Tumor, Salivary Gland Adenocarcinoma, Salivary Gland Adenoid Cystic Carcinoma, Salivary Gland Malignant Mixed Cell Type Tumor	LAPATINIB	Its record names the disease	ClinicalTrials.gov
NCT03990571	Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma	Phase 2	40	2024-08-26	Metastatic Adenoid Cystic Carcinoma, Progressive Disease, Recurrent Adenoid Cystic Carcinoma	AVELUMAB, AXITINIB	Its record names the disease	ClinicalTrials.gov
NCT02098538	Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma	Phase 2	38	2025-09-10	Adenoid Cystic Carcinoma	REGORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT01524692	Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma	Phase 2	35	2018-05-07	Adenoid Cystic Carcinoma	DOVITINIB	Its record names the disease	ClinicalTrials.gov
NCT01558661	Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma	Phase 2	33	2017-11-28	Adenoid Cystic Carcinoma	AXITINIB	Its record names the disease	ClinicalTrials.gov
NCT01175980	Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma	Phase 2	30	2020-08-03	Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage III Major Salivary Gland Cancer AJCC v7, Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Tongue Carcinoma	VORINOSTAT	Its record names the disease	ClinicalTrials.gov

1 to 10 of 55

See all 55 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cohort 1 - AL101 4mg vs Cohort 2 - AL101 6mg: deaths from any cause	41 of 45	26 of 42	87	NCT03691207	Trial comparisons
Cohort 1 - AL101 4mg vs Cohort 2 - AL101 6mg: serious adverse events	23 of 45	26 of 42	87	NCT03691207	Trial comparisons
Cohort 1 - AL101 4mg vs Cohort 2 - AL101 6mg: Overall Response Rate (ORR)	3 of 41	2 of 36	77	NCT03691207	Trial comparisons
Cohort 1 - AL101 4mg vs Cohort 2 - AL101 6mg: Clinical Benefit Response Rate (CBR)	28 of 41	24 of 36	77	NCT03691207	Trial comparisons
R/M Adenoid Cystic Carcinoma (ACC) vs R/M SGC of Any Histology, Except ACC (Non ACC): deaths from any cause	6 of 32	7 of 32	64	NCT03172624	Trial comparisons
R/M Adenoid Cystic Carcinoma (ACC) vs R/M SGC of Any Histology, Except ACC (Non ACC): serious adverse events	18 of 32	9 of 32	64	NCT03172624	Trial comparisons
Adenoid Cystic Carcinoma vs Non Adenoid Cystic Carcinoma: serious adverse events	12 of 40	8 of 14	54	NCT00859937	Trial comparisons
Pembrolizumab + Radiation vs Pembrolizumab: Number of Participants With Complete Response (Absence of Non-irradiated Lesions on Scans)	0 of 10	0 of 10	20	NCT03087019	Trial comparisons
Pembrolizumab + Radiation vs Pembrolizumab: Number of Participants With Partial Response (Tumor Size on Scans)	0 of 10	0 of 10	20	NCT03087019	Trial comparisons
Pembrolizumab + Radiation vs Pembrolizumab: deaths from any cause	1 of 10	1 of 10	20	NCT03087019	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials38

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40979299	RESULT	1	PubMed
39097677	RESULT	1	PubMed
37097003	RESULT	2	PubMed
25456010	RESULT	1	PubMed
24596143	RESULT	1	PubMed
24033920	RESULT	1	PubMed
21612974	RESULT	1	PubMed
17960615	RESULT	2	PubMed
17761983	RESULT	1	PubMed
16757203	RESULT	1	PubMed

1 to 10 of 38

See all 38 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004971

GET https://conductscience.org/api/diseases/v1/MONDO_0004971/drugs?page=2

API reference For AI assistants